Cambridge Healthtech Institute’s Sixth Annual
Optimisation and Development of Biologics

Strategies for Candidate Selection and Enhancement of Product Properties

2-3 November 2015

This track on Optimisation and Development of Biotherapeutics presents an exciting range of approaches for new biotherapeutics and those already under development. Big pharma and the larger biotechs will present their strategies and approaches to enable attendees to work out how to do the right thing at the right time in order to avoid hurdles further down the line.

This track presents strategies for selecting products with unique characteristics, and for optimisation of affinity, specificity, potency and clearance, and minimisation of side effects. It presents delivery approaches to enhance targeting of specific tissues, optimisation of formulation and manufacture, and preclinical evaluation.

Preliminary Agenda


Protein Engineering for New Modes of Actions and New Targets

Andreas Plückthun, Ph.D., Director and Professor, Biochemistry, University of Zurich

Targeting Ion Channels

Tristan J. Vaughan, Ph.D., Senior Director, Antibody Discovery & Protein Engineering, MedImmune Ltd.

Current and Future Trends in Antibody Therapeutics

Paul W.H.I. Parren, Ph.D., Senior Vice President & Scientific Director, Preclinical Development & Research, Genmab B.V. 


Purpose Oriented Antibody Libraries for De Novo Generation of pH-Dependent Antibodies

Nicolas Fischer, Ph.D., Head, Research, Novimmune SA

Augmented Binary Substitution: Simultaneous Ultra-Humanisation, CDR Redundancy Minimisation and Stabilisation of Antibodies for Human Therapy

William Finlay, Ph.D., Senior Director, Global Biotherapeutics, Pfizer, Inc.



Exploiting the Advantages of Bicyclic Peptide Therapeutics / Phage Selection of Bicyclic Peptides for Application as Therapeutics

Christian Heinis, Ph.D., Professor, Institute of Chemical Sciences and Engineering, Ecole Polytechnique Federale de Lausanne (EPFL)

Two Bispecific Antibodies Recognising Two Ligands for Rheumatoid Arthritis: Increased Potency with the Binder with more Valency for the Target

Alain Tissot, Ph.D., Director, Immune Biology, Roche Pharma Research and Early Development, Roche Innovation Center


pH and Calcium Dependent Fully Human Biparatopic IgG Antibody for Efficient Elimination of Soluble Antigen from Plasma

Eriko Murata, Master of Pharmacy, Research Scientist, Discovery Research, Chugai Pharmaceutical Co. Ltd.

ARGX-113, a Novel Fc -Based Therapeutic Approach for Antibody-Induced Pathologies

Peter Ulrichts, Ph.D., Senior Scientist, ArGEN-x


Early Stage Developability Assessment of Biotherapeutics

Laura Lin, Ph.D., Director, Global BioTherapeutic Technologies, Pfizer, Inc.

Compiling Preclinical Activities to Support IND Enabling for MGT010, a DART Product for Autoimmune Disease 

Paul Moore, Vice President, Cell Biology & Immunology, Macrogenics, Inc.

Preclinical Studies with FynomAbs, Fynomer-Antibody Fusion Proteins

Vanessa Baeriswyl, Ph.D., Scientist, Covagen AG, one of the Janssen Pharmaceutical Companies of J&J 


Implementation of an Integrated High Throughput Formulation Screening for Biologics

Michael Siedler, Ph.D., Section Head, NBE Formulation Sciences & Process Development, AbbVie Deutschland GmbH & Co KG

Delivery of Single Domain Antibody Biotherapeutics to the Brain

Frank Walsh, CEO, Ossianix; Professor, Kings College London

Oral Delivery of Anti-TNF-Alpha Nanofitin Shows a Strong Preventive and Curative Anti-Inflammatory Effect in Models of Inflammatory Bowel Diseases

Mathieu Cinier, Ph.D., Scientific Director, Affilogic

For more details on the conference, please contact: 

Nicole Lyscom, Ph.D.
Conference Director
Cambridge Healthtech Institute
Tel: +44 7791 866489

For partnering and sponsorship information, please contact: 

Carol Dinerstein,
Director, Business Development
Cambridge Healthtech Institute
Tel: 1 781-972-5471

Jason Gerardi
Business Development Manager
Cambridge Healthtech Institute
Tel: 781-972-5452